Loading...

Tissue Repair Ltd

TRP.AXASX
Healthcare
Biotechnology
A$0.28
A$-0.01(-1.72%)

Tissue Repair Ltd (TRP.AX) Financial Performance & Income Statement Overview

Explore the financials of Tissue Repair Ltd (TRP.AX), including yearly and quarterly data on income, cash flow, and balance sheets.

Revenue Growth
4849.28%
4849.28%
Operating Income Growth
-13.52%
13.52%
Net Income Growth
0.87%
0.87%
Operating Cash Flow Growth
-16.35%
16.35%
Operating Margin
-232.28%
232.28%
Gross Margin
99.78%
99.78%
Net Profit Margin
-186.12%
186.12%
ROE
-26.42%
26.42%
ROIC
-35.54%
35.54%

Tissue Repair Ltd (TRP.AX) Income Statement & Financial Overview

Explore comprehensive income reports for Tissue Repair Ltd TRP.AX, broken down by year and quarter.

MetricQ2 2025Q4 2024Q2 2024Q4 2023
Revenue$654319.00$1.73M$58586.00$3076.00
Cost of Revenue$0.00$5218.00$916952.00$1530.00
Gross Profit$654319.00$1.73M-$858366.00$1546.00
Gross Profit Ratio$1.00$1.00-$14.65$0.50
R&D Expenses$1.76M$2.25M$987101.00$840682.00
SG&A Expenses$2.09M$1.83M$688139.00$1.52M
Operating Expenses$3.84M$4.08M$1.68M$2.36M
Total Costs & Expenses$3.84M$4.09M$2.59M$2.36M
Interest Income$0.00$695052.00$395850.00$315979.00
Interest Expense$0.00$0.00$0.00$0.00
Depreciation & Amortization$2583.00$1830.00$814.00$1530.00
EBITDA-$3.19M-$2.34M-$2.26M-$1.99M
EBITDA Ratio-$4.88-$1.35-$38.51-$765.54
Operating Income-$3.19M-$2.35M-$2.53M-$2.36M
Operating Income Ratio-$4.88-$1.36-$43.25-$766.04
Other Income/Expenses (Net)$629171.00-$1.17M$276597.00$367529.00
Income Before Tax-$2.56M-$3.52M-$2.26M-$1.99M
Income Before Tax Ratio-$3.91-$2.03-$38.52-$646.55
Income Tax Expense$0.00-$1.64M-$4.00-$968579.00
Net Income-$2.56M-$1.88M-$2.26M-$1.02M
Net Income Ratio-$3.91-$1.09-$38.52-$331.67
EPS-$0.04-$0.03-$0.04-$0.02
Diluted EPS-$0.04-$0.03-$0.04-$0.02
Weighted Avg Shares Outstanding$60.40M$60.46M$60.46M$60.46M
Weighted Avg Shares Outstanding (Diluted)$60.40M$60.46M$60.46M$60.46M

Over the last four quarters, Tissue Repair Ltd achieved steady financial progress, growing revenue from $3076.00 in Q4 2023 to $654319.00 in Q2 2025. Gross profit stayed firm with margins at 100% in Q2 2025 versus 50% in Q4 2023. Operating income totaled -$3.19M in Q2 2025, maintaining a -488% margin over recent quarters. Despite shifts in R&D and SG&A costs, EBITDA stayed strong at -$3.19M. Net income dropped to -$2.56M, with EPS at -$0.04. Disciplined expense strategies and efficient operations ensured sustained profitability and long-term financial stability.

Unlock 25+ Years of Financial Data

Get access to extended historical data, advanced metrics, and more with our premium plan

Frequently Asked Questions

;